Aurinia Pharmaceuticals ( (AUPH) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals’ stock took a hit after Leerink downgraded the company from Outperform to Market Perform. The downgrade was driven by concerns over the long-term sales potential of Lupkynis, despite its successful commercialization. Additionally, competitive challenges surrounding aritinercept have raised questions about its differentiation in the market.
More about Aurinia Pharmaceuticals
YTD Price Performance: 84.38%
Average Trading Volume: 1,786,209
Technical Sentiment Signal: Buy
Current Market Cap: $2.13B
For further insights into AUPH stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.